{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tosi A"],"funding":["Università degli Studi di Padova","Fidia Farmaceutici"],"pagination":["109"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11005197"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43(1)"],"pubmed_abstract":["Background
The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induced 75 and 40% of complete response (CR) after 12 weeks of intensive phase and 12 months of maintenance phase, respectively. The aim of this study was to provide a detailed description of the tumor microenvironment (TME) of ONCOFID-P-B™-treated BCG-unresponsive bladder CIS patients enrolled in the NCT04798703 phase I study, in order to identify predictive biomarkers of response.Methods
The composition and spatial interactions of tumor-infiltrating immune cells and the expression of the most relevant hyaluronic acid (HA) receptors on cancer cells, were analyzed"],"journal":["Journal of experimental & clinical cancer research : CR"],"pubmed_title":["A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment."],"pmcid":["PMC11005197"],"funding_grant_id":["Specific grant to AR"],"pubmed_authors":["Bortoluzzi S","Parisatto B","Gaffo E","Rosato A","Tosi A"],"additional_accession":[]},"is_claimable":false,"name":"A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.","description":"Background
The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induced 75 and 40% of complete response (CR) after 12 weeks of intensive phase and 12 months of maintenance phase, respectively. The aim of this study was to provide a detailed description of the tumor microenvironment (TME) of ONCOFID-P-B™-treated BCG-unresponsive bladder CIS patients enrolled in the NCT04798703 phase I study, in order to identify predictive biomarkers of response.Methods
The composition and spatial interactions of tumor-infiltrating immune cells and the expression of the most relevant hyaluronic acid (HA) receptors on cancer cells, were analyzed","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T23:36:07.114Z","creation":"2024-11-13T18:32:00.677Z"},"accession":"S-EPMC11005197","cross_references":{"pubmed":["38600583"],"doi":["10.1186/s13046-024-03028-5"]}}